Accelerate your clinical development by partnering with a CRO that is structured to keep study teams focused on execution. This commitment to quality extends to the projects we engage in – we are selective to ensure we deliver the highest levels of service and partnering. Our unique approach has been preserved by 30+ years of organic growth – delivering consistency and stability while avoiding the disruptions associated with mergers and acquisitions.
While other CROs are busy merging— Medpace is busy managing.
A History of Organic Growth
For over 30 years, Medpace has remained steadfast in its commitment to organic growth, avoiding disruptions often associated with mergers and acquisitions. While the industry experiences consolidation, we’ve maintained our focus on disciplined, organic expansion. This approach preserves our unique processes, ensuring we deliver exceptional service. As a result, Medpace has emerged as a leader, leveraging our extensive footprint to provide unparalleled support to Sponsors.
Medpace values the strategic significance of our partnerships, which is why we adopt a selective approach to collaboration. By evaluating each opportunity based on the Sponsor’s scientific alignment, regulatory plan, and financial strategies, we ensure that our resources are directed where they can make the most impact. This selection process allows us to bid on projects where we can provide comprehensive support as a full-service CRO, leveraging our expertise, experience, and execution capabilities.
“We only work where we are confident that we can truly add value. All of our executions start in the medical science. We bring with us a sense of responsibility and ownership, and we really want to be the right partner, the seamless extension of the Sponsor team, to help them get this new therapeutic modality to market.”
Reinilde Heyrman, MD Chief Medical Officer, Medical Department, Medpace
